失眠药物治疗市场－全球产业规模、份额、趋势、机会、预测：按药物、疗法、分销管道、地区和竞争对手划分，2021-2031年

全球失眠药物治疗市场预计将从 2025 年的 40.3 亿美元成长到 2031 年的 56.3 亿美元，复合年增长率为 5.73%。

此领域涵盖多种处方药和非处方药，旨在促进入睡和维持睡眠，包括苯二氮平类药物、非苯二氮平类药物、Orexin受体拮抗剂和褪黑激素促效剂。推动该领域成长的主要因素是全球睡眠障碍的增加，这源于现代生活的压力以及老龄化社会对昼夜节律紊乱的易感性。此外，医疗保健支出的增加以及人们对睡眠卫生在预防医学中重要作用的认识不断提高，也促进了该行业的持续增长。

儘管市场呈现强劲成长趋势，但长期使用镇静剂可能导致依赖，并引发安全隐患，这些都构成了市场面临的重大障碍，因此需要更严格的监管，也造成了患者的抵触情绪。儘管对有效治疗方法的需求依然迫切，但这些安全问题仍然使治疗格局变得复杂。根据美国睡眠医学会预测，到2024年，将有12%的美国人被诊断出患有慢性失眠，凸显出庞大的患者群体亟需能够有效平衡临床疗效和长期安全性的药物治疗方案。

市场驱动因素

慢性失眠和睡眠障碍的日益普遍是推动全球失眠药物市场扩张的主要动力。这种成长动能源自于高压力的都市生活方式和不断上升的合併精神健康问题，使得当行为改变不足以改善睡眠时，医疗介入变得不可或缺。随着睡眠不足演变为公共卫生危机，处方药的目标族群也从暂时性失眠患者扩展到有慢性临床需求的患者。 RiskStrategies 于 2025 年 6 月发布的关于失眠经济负担的报告估计，慢性失眠将影响 10% 至 15% 的普通人群，从而产生持续的需求。因此，医疗保健提供者必须将睡眠问题作为慢性病管理的重要组成部分。

新型药物，特别是双Orexin受体拮抗剂（DORA）的研发进展，是推动市场成长要素，促使市场转向更安全、成瘾性更低的治疗方法。这些治疗方法透过抑制觉醒路径而非诱导全身镇静，解决了传统药物成瘾和认知障碍等问题。这种转变带来了显着的财务效益。例如，Eisai在2025年5月的财务报告中披露，其失眠治疗药物Devigo的销售额达到538亿日圆。同样，Idolsia公司宣布，其产品在2025年第一季获得了超过1,000万张睡眠处方，显示患者对这些创新作用机制的接受度很高。

市场挑战

长期使用镇静剂带来的安全隐患和依赖风险是全球失眠药物市场成长的主要障碍。这些问题需要严格的监管，增加了药物研发和市场核准的成本和复杂性。监管机构通常要求在镇静剂和催眠药上标註严格的警告标籤，并限制处方指南，迫使医疗服务提供者缩短治疗疗程。因此，医生往往优先考虑短期缓解症状而非长期治疗，以最大限度地降低依赖风险，从而导致重复处方减少。

此外，频繁出现的不良反应会导致患者犹豫是否继续治疗，从而降低用药依从性，并限制潜在益处。出现功能障碍的患者更有可能停止用药。根据2024年睡眠基金会的数据，79%使用处方助眠药物的成年人报告称，第二天会出现嗜睡、困倦和注意力难以集中等残留症状。如此高的不利事件发生率加剧了消费者的疑虑，限制了药物疗法的推广，最终阻碍了该行业的商业性扩张。

市场趋势

选择性Orexin-2受体拮抗剂（SORA）的临床发展标誌着精准医疗的转变，这与现有双重Orexin受体拮抗剂更广泛的作用机制截然不同。与目前旨在抑制整体觉醒的疗法不同，这些新一代药物针对特定的受体亚型，从而能够针对复杂的表型（包括合併精神疾病的患者）进行个人化治疗。这种方法旨在将疗效与不良的镇静作用区分开来，满足那些对标准抗忧郁症无反应的患者群体的需求。强生公司在2024年5月的新闻稿中强调了此类专业介入措施的必要性，指出约60%的重度忧郁症（MDD）患者存在残余性失眠。

同时，药物治疗与处方数位疗法的整合正在改变市场格局，创造出融合药物治疗和行为疗法软体的混合护理模式。这一趋势透过使用FDA批准的数位工具作为第一线或辅助性治疗，降低了安全隐患，同时减少了对高剂量、长期镇静剂的依赖，并促进了患者参与治疗。真实世界数据支持了这个多面向策略的有效性。根据Knox Medical在2024年6月举行的SLEEP 2024会议上发表的一项分析，在超过1500名患者中，数位认知行为疗法（dCBT-I）的依从性达到了58%，证实了将数位解决方案与传统药物治疗相结合的潜力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：失眠药物治疗的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类型（非处方药、非处方助眠药、非处方睡眠补充剂、处方药）
  • 治疗方法（非处方助眠药、处方助眠药）
  • 分销通路（药局、电子商务、医​​院药局、零售药局）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美失眠药物治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲失眠药物治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区失眠药物治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲失眠药物治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲失眠药物治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球失眠药物治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck & Co Inc
• Ebb Therapeutics Inc/US
• Pfizer Inc
• Sanofi SA
• Takeda Pharmaceutical Co Ltd
• Paratek Pharmaceuticals Inc
• Electromedical Products International Inc
• Meda Pharmaceuticals Inc
• Purdue Pharma LP
• Pernix Therapeutics Holdings Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Insomnia Pharmacological Treatment Market is projected to expand from USD 4.03 Billion in 2025 to USD 5.63 Billion by 2031, reflecting a CAGR of 5.73%. This sector comprises a diverse array of prescription and over-the-counter medications, such as benzodiazepines, non-benzodiazepines, orexin receptor antagonists, and melatonin agonists, all aimed at facilitating sleep onset or maintenance. Growth is primarily fueled by the rising global incidence of sleep disorders resulting from high-stress modern living and an aging population prone to circadian rhythm issues. Additionally, rising healthcare spending and a fundamental cultural shift viewing sleep hygiene as essential to preventative health serve as enduring drivers for the industry.

Despite these positive growth trajectories, the market encounters substantial obstacles related to safety concerns and the potential for dependency with long-term sedative use, which necessitate stringent regulations and cause patient reluctance. These safety issues complicate the therapeutic landscape even though the demand for effective treatments remains critical. According to the American Academy of Sleep Medicine, 12% of Americans reported a diagnosis of chronic insomnia in 2024, underscoring the significant population requiring pharmacological solutions that effectively balance clinical efficacy with long-term safety profiles.

Market Driver

The increasing prevalence of chronic insomnia and sleep disorders acts as the primary catalyst for the expansion of the Global Insomnia Pharmacological Treatment Market. This momentum is driven by the convergence of high-stress urban lifestyles and rising rates of mental health comorbidities, creating a need for medical intervention when behavioral changes fail. As sleep deprivation escalates into a public health crisis, the target demographic for prescription therapies has broadened from transient sufferers to those with chronic clinical needs. A June 2025 report by Risk Strategies on the economic burden of insomnia estimates that chronic insomnia affects 10-15% of the general population, creating sustained demand that compels healthcare providers to treat sleep issues as a vital part of chronic disease management.

Advancements in novel drug classes, particularly dual orexin receptor antagonists (DORAs), represent a second major growth factor by moving the market toward safer, non-habit-forming treatments. These therapies inhibit wakefulness pathways rather than inducing generalized sedation, addressing historical concerns regarding dependency and cognitive impairment. This shift is generating significant financial results; for instance, Eisai Co., Ltd. reported 53.8 billion yen in revenue for its insomnia treatment, Dayvigo, in their May 2025 financial report. Similarly, Idorsia noted in 2025 that over 10 million nights of sleep were prescribed for their product in the first quarter, demonstrating robust patient uptake of these innovative mechanisms.

Market Challenge

Safety concerns and the risk of dependency linked to long-term sedative use present a major obstacle to the growth of the Global Insomnia Pharmacological Treatment Market. These issues necessitate rigorous regulatory oversight, which escalates the cost and complexity associated with drug development and market approval. Authorities often enforce strict warning labels and limit prescribing guidelines for sedative-hypnotics, forcing healthcare providers to restrict the duration of therapy. Consequently, the volume of repeat prescriptions declines as physicians prioritize short-term symptom relief over long-term management to minimize addiction risks.

Furthermore, the frequency of adverse side effects generates significant patient hesitancy and lowers treatment adherence, thereby limiting revenue potential. Patients experiencing functional impairment are prone to discontinuing medication; data from the Sleep Foundation in 2024 indicates that 79% of adults using prescription sleep aids reported residual effects such as oversleeping, grogginess, or difficulty concentrating the following day. This high incidence of negative outcomes reinforces skepticism among consumers and restricts the widespread adoption of pharmacological interventions, ultimately hindering the sector's commercial expansion.

Market Trends

The clinical evolution of Selective Orexin-2 Receptor Antagonists (SORAs) marks a shift toward precision medicine, distinguishing itself from the broader mechanism of existing dual orexin receptor antagonists. Unlike current therapies that generally suppress wakefulness, this next-generation class targets specific receptor subtypes to tailor treatments for complex phenotypes, including patients with psychiatric comorbidities. This approach aims to separate efficacy from unwanted sedation, filling a gap for those unresponsive to standard antidepressants. Highlighting the need for such specialized interventions, a May 2024 press release from Johnson & Johnson noted that approximately 60% of patients with Major Depressive Disorder (MDD) suffer from residual insomnia symptoms.

Simultaneously, the integration of pharmacotherapy with prescription digital therapeutics is transforming the market by creating hybrid care models that blend medicinal treatments with behavioral software. This trend mitigates safety concerns by employing FDA-cleared digital tools as either first-line or complementary therapies, which helps reduce reliance on high-dose, long-term sedatives while enhancing patient engagement. Real-world data supports the viability of this multimodal strategy; a June 2024 analysis presented by Nox Medical at the SLEEP 2024 conference revealed a 58% adherence rate to digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) among over 1,500 patients, confirming the feasibility of combining digital solutions with traditional medication.

Key Market Players

• Merck & Co Inc
• Ebb Therapeutics Inc/US
• Pfizer Inc
• Sanofi SA
• Takeda Pharmaceutical Co Ltd
• Paratek Pharmaceuticals Inc
• Electromedical Products International Inc
• Meda Pharmaceuticals Inc
• Purdue Pharma LP
• Pernix Therapeutics Holdings Inc

Report Scope

In this report, the Global Insomnia Pharmacological Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Insomnia Pharmacological Treatment Market, By Drug

• OTC Drugs
• OTC Sleep Aids
• OTC Sleep Supplements
• Prescription Drugs

Insomnia Pharmacological Treatment Market, By Treatment

• Over-the-Counter Sleep Aids
• Prescription Sleep Aids

Insomnia Pharmacological Treatment Market, By Distribution Channel

• Drug Stores
• E-Commerce
• Hospital Pharmacies
• Retail Pharmacies

Insomnia Pharmacological Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Insomnia Pharmacological Treatment Market.

Available Customizations:

Global Insomnia Pharmacological Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Insomnia Pharmacological Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (OTC Drugs, OTC Sleep Aids, OTC Sleep Supplements, Prescription Drugs)
  • 5.2.2. By Treatment (Over-the-Counter Sleep Aids, Prescription Sleep Aids)
  • 5.2.3. By Distribution Channel (Drug Stores, E-Commerce, Hospital Pharmacies, Retail Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Insomnia Pharmacological Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Insomnia Pharmacological Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Insomnia Pharmacological Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Insomnia Pharmacological Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Insomnia Pharmacological Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Insomnia Pharmacological Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Insomnia Pharmacological Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Insomnia Pharmacological Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Insomnia Pharmacological Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Insomnia Pharmacological Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Insomnia Pharmacological Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Insomnia Pharmacological Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Insomnia Pharmacological Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Insomnia Pharmacological Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Insomnia Pharmacological Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Insomnia Pharmacological Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Insomnia Pharmacological Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Insomnia Pharmacological Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Insomnia Pharmacological Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Insomnia Pharmacological Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. South America Insomnia Pharmacological Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Insomnia Pharmacological Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Insomnia Pharmacological Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Insomnia Pharmacological Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Insomnia Pharmacological Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Ebb Therapeutics Inc/US
• 15.3. Pfizer Inc
• 15.4. Sanofi SA
• 15.5. Takeda Pharmaceutical Co Ltd
• 15.6. Paratek Pharmaceuticals Inc
• 15.7. Electromedical Products International Inc
• 15.8. Meda Pharmaceuticals Inc
• 15.9. Purdue Pharma LP
• 15.10. Pernix Therapeutics Holdings Inc

16. Strategic Recommendations

17. About Us & Disclaimer